Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Adenosine A2A receptor antagonist

DRUG CLASS:

Adenosine A2A receptor antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	zimberelimab + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB928 Sensitive : C2	zimberelimab + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB928 Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	apalutamide + AZD4635 Sensitive: D – Preclinical apalutamide + AZD4635 Sensitive : D	apalutamide + AZD4635 Sensitive: D – Preclinical apalutamide + AZD4635 Sensitive : D
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	AZD4635 Sensitive: D – Preclinical AZD4635 Sensitive : D	AZD4635 Sensitive: D – Preclinical AZD4635 Sensitive : D